In addition, TSA treatment suppressed the proliferation of ovarian cancer cell lines; interestingly, it exhibited an even higher cytotoxic effect on HF1/TP53/KRAS/MYC cells than on HF1 cells (Supplementary Fig. 3f). The gene discussed is KRAS; the disease is ovarian carcinoma.